Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Like the name says, antisperm antibodies fight sperm. It happens when the immune system mistakenly targets sperm in a man’s semen as an invader and damages or kills it. Antisperm antibodies aren ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components ...

Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more ...

The French pharma is handing over $125 million upfront, with a near-term payment of $50 million to follow, for the exclusive worldwide rights to a pair of bispecific antibodies. HXN-1002 targets ...

checkpoint inhibitor as well as which patients with NSCLC would benefit from Regeneron's Libtayo (cemiplimab). "With the current European indication expansion of PD-L1 IHC 22C3 PharmDx into gastric or ...

In the collaboration, BigHat will deploy its Milliner platform, a suite of state-of-the-art ML technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer ...